Page All:
Page 1
Thomson Reuters Launches Pharmacy Intervention Solution for Hospital Pharmacists
ANN ARBOR, Mich., March 1 -- Thomson Reuters announced today the launch of its new Pharmacy Intervention solution for hospitals.
This solution combines real-time clinical surveillance, mobile access to patient data, and Micromedex reference information. It helps hospital pharmacists identify, perform, and document interventions at the point of care, prevent adverse drug events, and reduce medication costs.
Thomson Reuters Pharmacy Intervention compares clinical profiles with data pulled from disparate hospital IT systems to automatically identify patients who are at-risk of an adverse drug event, such as someone who is on a potentially lethal combination or dosage of medications. It also helps pharmacists reduce hospital costs by identifying alternative, yet equally effective, medication therapies -- such as a lower-cost oral medication in place of a drug administered intravenously.
Pharmacists can access patient information from a web portal or mobile device -- such as a BlackBerry® Smartphone or tablet PC -- and document their intervention directly at the point of care. Each intervention is attached directly to the patient record and can be viewed by all relevant care team members at any time.
"Pharmacy Intervention will be a great addition to our hospital and will help our pharmacists improve their workflow. With it, they will be able to monitor their patients' medication needs more efficiently, document their interventions at the point of care, and improve patient safety," said Christine Soedel, clinical pharmacy coordinator at Columbus Regional Hospital. "Using the targeted clinical profiles will allow our pharmacists to more easily identify patients most in need of medication therapy, respond to them immediately, and prevent a potential adverse drug event."
Pre-built profiles based on Micromedex reference information cover the following categories: antimicrobial monitoring, anticoagulation monitoring, glycemic monitoring, intravenous-to-oral conversion, narrow therapeutic indexing, and patient safety.
Pharmacy Intervention is part of the Clinical Xpert(TM) suite of clinical workflow solutions that has been the category leader for mobile data systems in the Best in KLAS Awards for eight consecutive years.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE:TRI). For more information, go to http://www.thomsonreuters.com.
Source: Thomson Reuters
CONTACT: David Wilkins, +1-734-913-3397,
David.wilkins@thomsonreuters.com
Web Site: http://www.thomsonreuters.com/
Thomson Reuters Launches Pharmacy Intervention Solution for Hospital Pharmacists
ANN ARBOR, Mich., March 1 -- Thomson Reuters announced today the launch of its new Pharmacy Intervention solution for hospitals.
This solution combines real-time clinical surveillance, mobile access to patient data, and Micromedex reference information. It helps hospital pharmacists identify, perform, and document interventions at the point of care, prevent adverse drug events, and reduce medication costs.
Thomson Reuters Pharmacy Intervention compares clinical profiles with data pulled from disparate hospital IT systems to automatically identify patients who are at-risk of an adverse drug event, such as someone who is on a potentially lethal combination or dosage of medications. It also helps pharmacists reduce hospital costs by identifying alternative, yet equally effective, medication therapies -- such as a lower-cost oral medication in place of a drug administered intravenously.
Pharmacists can access patient information from a web portal or mobile device -- such as a BlackBerry® Smartphone or tablet PC -- and document their intervention directly at the point of care. Each intervention is attached directly to the patient record and can be viewed by all relevant care team members at any time.
"Pharmacy Intervention will be a great addition to our hospital and will help our pharmacists improve their workflow. With it, they will be able to monitor their patients' medication needs more efficiently, document their interventions at the point of care, and improve patient safety," said Christine Soedel, clinical pharmacy coordinator at Columbus Regional Hospital. "Using the targeted clinical profiles will allow our pharmacists to more easily identify patients most in need of medication therapy, respond to them immediately, and prevent a potential adverse drug event."
Pre-built profiles based on Micromedex reference information cover the following categories: antimicrobial monitoring, anticoagulation monitoring, glycemic monitoring, intravenous-to-oral conversion, narrow therapeutic indexing, and patient safety.
Pharmacy Intervention is part of the Clinical Xpert(TM) suite of clinical workflow solutions that has been the category leader for mobile data systems in the Best in KLAS Awards for eight consecutive years.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto Stock Exchange (TSX: TRI) and New York Stock Exchange (NYSE:TRI). For more information, go to http://www.thomsonreuters.com.
Source: Thomson Reuters
CONTACT: David Wilkins, +1-734-913-3397,
David.wilkins@thomsonreuters.com
Web Site: http://www.thomsonreuters.com/